Physician profile
David Steinberger
NPI 1275501207
$564.31
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $123 · 2022: $150.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $149.99 | 2022 | |
| Glaxosmithkline, LLC. | $89.99 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $77.73 | 2019-2020 | |
| Pfizer INC. | $56.49 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $42.14 | 2019-2020 | |
| Astellas Pharma US INC | $32.10 | 2019 | |
| Sanofi Pasteur INC. | $21.67 | 2019 | |
| Shire North American Group INC | $19.82 | 2019 | |
| Allergan, INC. | $17.42 | 2020 | |
| Amgen INC. | $17.28 | 2019 | |
| Fortovia Therapeutics, INC. | $15.60 | 2019 | |
| Lilly USA, LLC | $12.28 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Steinberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.